ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO357

Characterization of Metoprolol and Metabolite Concentrations Pre and Post Hemodialysis: Potential Implications for Intradialytic Hypotension and Post-Dialysis Fatigue

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1800 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

  • Dean, Michael C., University of Michigan, Ann Arbor, Michigan, United States
  • Costello, Gabrielle M., University of Michigan, Ann Arbor, Michigan, United States
  • Souza, Ernane, University of Michigan, Ann Arbor, Michigan, United States
  • Felton, Jeremy Antonio, University of Michigan, Ann Arbor, Michigan, United States
  • Szamosfalvi, Balazs, University of Michigan, Ann Arbor, Michigan, United States
  • Pai, Manjunath P., University of Michigan, Ann Arbor, Michigan, United States
  • Pai, Amy Barton, University of Michigan, Ann Arbor, Michigan, United States
Background

Previous pharmacokinetic (PK) studies of metoprolol succinate (MPL) were conducted before high-flux HD and did not evaluate post-HD rebound or parent:metabolite (P:M) ratios. Intercompartmental redistribution of antihypertensives may contribute to intradialytic hypotension and post-dialysis fatigue. The aim of this study was to characterize the PK of MPL and α-hydroxymetoprolol during and post-HD.

Methods

Eligible patients were >18 years, on HD 3 days a week for 3.5-5 hours (h), daily dose of MPL 25-200mg, and hemoglobin >9.5 g/dL. Arterio-venous (AV) paired samples were collected prior to HD initiation, 0.5h, 2h, and end of treatment. Post-HD sampling occurred at 0.5, 2, and 4h. Serum samples were assayed by liquid chromatography-tandem mass spectrometry and a non-parametric population PK model was used (PMetricsTM LAPK). T0 samples were analyzed for CYP2D6*4.

Results

Eight patients (5 male, 3 female; Age 59±17 years) were enrolled. The MPL PK data were best fit with a linear, 2-compartment model with absorption rate and fraction absorbed fixed to known values from literature. The model predicted MPL clearance (CL) was relatively unchanged on- and post-HD with a mean (CV) of 46.5 (17.4%) and 41.9 (54.4%) L/h, respectively. AV-dialytic CL was minimal (13.1±8.8% of total CL). The mean volume of distribution (Vd) in central compartment (Vc) decreased: 119.7 (103.2%) L on-HD to 18.4 (128.7%) L post-HD. Mean peripheral compartment Vd (Vp) increased: 17.7 (252.2%) L on-HD to 160.0 (0.0%) L post-HD. Vd changes resulted in significant MPL flux from Vp to Vc on-HD driven by redistribution and from Vc to Vp post-HD due to hemoconcentration. Higher MPL concentrations were seen at 2h on-HD and 4h post-HD. The P:M ratios were variable suggesting phenotypic differences in CYP2D6 activity. Three CYP2D6*4 heterozygotes were identified, but only one showed decreased metabolism based on P:M ratio.

Conclusion

Large changes in Vd due to ultrafiltration drive fluctuating MPL concentrations during and after HD, resulting in highly variable MPL serum concentrations. This may contribute to intradialytic hypotension and/or post-dialysis fatigue. Dialytic CL does not appear to contribute significantly to varying MPL concentration profiles.